News & Updates

Men with moderate erectile dysfunction (ED) may benefit from having 12 sessions of low-intensity shock wave therapy (SWT) twice weekly for 6 weeks, with a treatment protocol of 5,000 impulses, 0.0096 mJ/mm2 energy flux density, and 5-Hz frequency, suggests a study.

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.

First-line treatment with tumour necrosis factor-α (TNF-α) blockers is both safe and effective in children with inflammatory bowel disease (IBD), according to a recent study. Early drug initiation even cuts the likelihood of treatment failure and leads to fewer extraintestinal symptoms.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).